Wright Bonilla Quoted on DOJ Brief
November 5, 2010
BNA’s Patent, Trademark & Copyright Journal
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BNA’s Patent, Trademark & Copyright Journal on November 5, 2010 titled “DOJ’s ‘Questionable Reinterpretation’ of DNA Patentability Disappoints Patent Community.” Wright Bonilla discusses the patent community’s backlash against a brief filed by the U.S. Department of Justice as a friend of the court in the Myriad case on the patentability of genetic materials. She cautions against an overreaction to the DOJ’s brief, stating that Myriad’s composition claims directed to cDNA are patent eligible. She adds that the DOJ brief asserts this patent eligibility and meets the threshold of Section 101 of the Patent Act.
Related News
December 12, 2025
In the News
Foley Chairman and CEO Daljit Doogal Talks Firm Strategy and Growth, Featured in Media for Reelection
Foley & Lardner LLP Chairman and CEO Daljit Doogal is featured in The American Lawyer article, “Foley Board Taps Daljit Doogal for Second Term as Chair and CEO,” for his reelection to a second four-year term.
December 11, 2025
In the News
Carrie Hoffman Comments on SCOTUS Arbitration Jurisdiction Case
Foley & Lardner LLP partner Carrie Hoffman commented on the U.S. Supreme Court's decision to hear an arbitration jurisdiction case in the Law360 article, "High Court Arb. Jurisdiction Case May Impact W&H Cases."
December 10, 2025
In the News
Charles Gass Quoted on Health Care Implications of Colorado AI Act
Foley & Lardner LLP senior counsel Charles Gass detailed Colorado's Artificial Intelligence Act and its implications for health providers in the ColoradoBiz article, “Colorado leads nation on AI healthcare regulations.”